Durvalumab versus sugemalimab as consolidation therapy after definitive chemoradiotherapy for unresectable stage III non–small-cell lung cancer: a real-world comparative effectiveness study

Authors

Institutions

Publication Details

Journal
BMC Pulmonary Medicine
Published
2026-09-25
DOI
https://doi.org/10.1186/s12890-026-04769-z
Primary Topic
Lung Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Durvalumab versus sugemalimab as consolidation therapy after definitive chemoradiotherapy for unresectable stage III non–small-cell lung cancer: a real-world comparative effectiveness study

Yuting Zhao, Leilei Jiang, Wei Deng, Jiayi Xiao et al.
BMC Pulmonary Medicine
Lung Cancer Diagnosis and Treatment
article

Durvalumab versus sugemalimab as consolidation therapy after definitive chemoradiotherapy for unresectable stage III non–small-cell lung cancer: a real-world comparative effectiveness study

Yuting Zhao, Leilei Jiang, Wei Deng, Jiayi Xiao, Jiahui Shan, Xiao Chang, Liuhua Long, Yue Teng, Rong Yu, Anhui Shi, Jiayi Yu, Dan Yang, Huiming Yu, Weiyan Du, Xin Dong
article en

Abstract

No abstract available for this paper.
BMC Pulmonary Medicine
Peking University (CN), Peking University Cancer Hospital (CN), Heze Municipal Hospital (CN)
Good health and well-being
Openalex Percentile: Top 12%
Lung Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.